To study the role of BCL-XL in the tumor immune microenvironment, we chose several cell lines with which to produce syngeneic tumor models (MC38 for colon adenocarcinoma, 4T1 and Py8119 for breast cancer, and Renca for renal cancer). This evidence concerns the gene BCL2L1 and breast carcinoma.